11月21日，睿昂基因跌5.44%，成交额3290.94万元。两融数据显示，当日睿昂基因获融资买入额435.68 万元，融资偿还217.52万元，融资净买入218.16万元。截至11月21日，睿昂基因融资融券余额合计 5936.47万元。 分红方面，睿昂基因A股上市后累计派现1943.57万元。 融资方面，睿昂基因当日融资买入435.68万元。当前融资余额5936.47万元，占流通市值的4.02%，融资 余额低于近一年30%分位水平，处于低位。 责任编辑：小浪快报 融券方面，睿昂基因11月21日融券偿还0.00股，融券卖出0.00股，按当日收盘价计算，卖出金额0.00 元；融券余量0.00股，融券余额0.00元，超过近一年90%分位水平，处于高位。 资料显示，上海睿昂基因科技股份有限公司位于上海市奉贤区汇丰西路1817弄147号，成立日期2012年2 月17日，上市日期2021年5月17日，公司主营业务涉及体外诊断产品(包括检测仪器及检测试剂)的研 发、生产、销售及科研、检测服务,主要为血液病(白血病、淋巴瘤)、实体瘤(肺癌、结直肠癌、黑色素 瘤等)和传染病(乙型肝炎、风疹、单纯疱疹等)患者提供基因及抗原的精 ...

Group 1 - The core viewpoint of the news highlights the significant increase in the stock price of Ruian Gene, which rose by 9.95% on August 26, with a trading volume of 148 million yuan [1] - On August 26, Ruian Gene had a financing purchase amount of 20.89 million yuan and a net financing purchase of 2.7854 million yuan, indicating strong investor interest [1] - As of August 26, the total balance of margin trading for Ruian Gene was 71.03 million yuan, accounting for 3.70% of its market capitalization, which is above the 80th percentile of the past year [1] Group 2 - Ruian Gene, established on February 17, 2012, specializes in the research, production, and sales of in vitro diagnostic products, primarily focusing on precision testing for blood diseases, solid tumors, and infectious diseases [2] - The company's revenue composition includes 84.71% from self-produced reagents, 8.52% from testing services, and 1.90% from research services, indicating a strong reliance on its own products [2] - For the first quarter of 2025, Ruian Gene reported a revenue of 54.738 million yuan, a year-on-year decrease of 14.72%, while its net profit attributable to the parent company was 3.355 million yuan, showing a significant increase of 529.26% [2] Group 3 - Since its A-share listing, Ruian Gene has distributed a total of 10.0541 million yuan in dividends [3] - As of March 31, 2025, the number of shareholders for Ruian Gene was 3,990, a decrease of 6.54% from the previous period, while the average circulating shares per person increased by 6.99% [2][3] - Among the top ten circulating shareholders, Huaxia CSI 500 Index Enhanced A (007994) is a new entrant, holding 531,500 shares [3]